Published in Brain Behav Immun on November 09, 2013
Mechanisms of chemotherapy-induced behavioral toxicities. Front Neurosci (2015) 0.92
Inflammation-sleep interface in brain disease: TNF, insulin, orexin. J Neuroinflammation (2014) 0.90
The role of IL-1β and TNF-α signaling in the genesis of cancer treatment related symptoms (CTRS): a study using cytokine receptor-deficient mice. Brain Behav Immun (2014) 0.89
Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle. PLoS One (2014) 0.84
Sickness behavior induced by cisplatin chemotherapy and radiotherapy in a murine head and neck cancer model is associated with altered mitochondrial gene expression. Behav Brain Res (2015) 0.80
Induction of IL-6 by Cytotoxic Chemotherapy Is Associated With Loss of Lean Body and Fat Mass in Tumor-free Female Mice. Biol Res Nurs (2014) 0.79
Suppression of Locomotor Activity in Female C57Bl/6J Mice Treated with Interleukin-1β: Investigating a Method for the Study of Fatigue in Laboratory Animals. PLoS One (2015) 0.77
Dietary quercetin reduces chemotherapy-induced fatigue in mice. Integr Cancer Ther (2014) 0.76
Localized External Beam Radiation Therapy (EBRT) to the Pelvis Induces Systemic IL-1Beta and TNF-Alpha Production: Role of the TNF-Alpha Signaling in EBRT-Induced Fatigue. Radiat Res (2015) 0.75
Biological Basis for the Clustering of Symptoms. Semin Oncol Nurs (2016) 0.75
Time-of-Day Dictates Transcriptional Inflammatory Responses to Cytotoxic Chemotherapy. Sci Rep (2017) 0.75
Dexamethasone Chemotherapy Does Not Disrupt Orexin Signaling. PLoS One (2016) 0.75
Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer. J Surg Res (2017) 0.75
Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue. Pharmacol Res (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Dose translation from animal to human studies revisited. FASEB J (2007) 15.67
5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer (2003) 11.78
Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci (1998) 9.88
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell (1999) 9.84
Hypothalamic regulation of sleep and circadian rhythms. Nature (2005) 8.23
The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell (1999) 7.99
Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron (2005) 4.72
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist (2000) 3.62
Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci (2005) 3.53
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology (2002) 3.24
Fos expression in orexin neurons varies with behavioral state. J Neurosci (2001) 3.08
Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci (2002) 2.83
Arousal and reward: a dichotomy in orexin function. Trends Neurosci (2006) 2.79
Cytokine-induced sickness behavior. Brain Behav Immun (2003) 2.70
Afferents to the orexin neurons of the rat brain. J Comp Neurol (2006) 2.57
Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer (2003) 2.48
The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun (2006) 2.40
Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci U S A (1999) 2.39
Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J Neurosci (2009) 2.35
Mechanisms of cancer-related fatigue. Oncologist (2007) 2.25
Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer (2011) 2.18
Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther (2011) 2.12
Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat. J Neurosci (2001) 1.86
Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest (2000) 1.86
Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology (2005) 1.76
Cancer, fatigue and the return of patients to work-a prospective cohort study. Eur J Cancer (2003) 1.71
Neuronal activity of orexin and non-orexin waking-active neurons during wake-sleep states in the mouse. Neuroscience (2008) 1.62
Cancer-related fatigue: implications for breast cancer survivors. Cancer (2012) 1.53
Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol (2013) 1.48
Mechanism for Hypocretin-mediated sleep-to-wake transitions. Proc Natl Acad Sci U S A (2012) 1.41
Translational approaches to treatment-induced symptoms in cancer patients. Nat Rev Clin Oncol (2012) 1.38
Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res (2000) 1.37
The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol Res Nurs (2006) 1.37
Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun (2012) 1.36
Feeding and activity induced by orexin A in the lateral hypothalamus in rats. Regul Pept (2002) 1.35
Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism. C R Acad Sci III (1994) 1.33
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther (2011) 1.32
Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs (2007) 1.31
Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol (2003) 1.28
Orexin A (hypocretin 1) injected into hypothalamic paraventricular nucleus and spontaneous physical activity in rats. Am J Physiol Endocrinol Metab (2003) 1.27
Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain Behav Immun (2012) 1.23
Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am J Physiol Regul Integr Comp Physiol (2002) 1.23
Inflammation-induced lethargy is mediated by suppression of orexin neuron activity. J Neurosci (2011) 1.22
The diurnal rhythm of hypocretin in young and old F344 rats. Sleep (2004) 1.22
A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer (2013) 1.21
A systematic review of the association between immunogenomic markers and cancer-related fatigue. Brain Behav Immun (2012) 1.20
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage (2009) 1.15
Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology (2007) 1.13
Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology (Berl) (2011) 1.11
Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol (2004) 1.10
Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci (2011) 1.10
Vagotomy blocks behavioural effects of interleukin-1 injected via the intraperitoneal route but not via other systemic routes. Neuroreport (1996) 1.09
A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat (1983) 1.08
Development of a mouse model for assessing fatigue during chemotherapy. Comp Med (2011) 1.02
Orexin directly excites orexin neurons through orexin 2 receptor. J Neurosci (2010) 1.02
Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. PLoS One (2008) 0.99
Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin. Cancer Biol Ther (2012) 0.98
Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage (2011) 0.98
Daily intraparaventricular orexin-A treatment induces weight loss in rats. Obesity (Silver Spring) (2009) 0.97
Lipopolysaccharide challenge-induced suppression of Fos in hypothalamic orexin neurons: their potential role in sickness behavior. Brain Behav Immun (2009) 0.96
Exercise programs for cancer-related fatigue: evidence and clinical guidelines. J Natl Compr Canc Netw (2010) 0.92
Patients' experiences with cancer-related fatigue: a review and synthesis of qualitative research. Oncol Nurs Forum (2011) 0.91
Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster. Curr Opin Support Palliat Care (2013) 0.91
Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology (2011) 0.90
Lipopolysaccharide (LPS)- and muramyl dipeptide (MDP)-induced anorexia during refeeding following acute fasting: characterization of brain cytokine and neuropeptide systems mRNAs. Brain Res (1998) 0.89
Neurotensin co-expressed in orexin-producing neurons in the lateral hypothalamus plays an important role in regulation of sleep/wakefulness states. PLoS One (2013) 0.89
Effects of 5-fluorouracil chemotherapy on fatigue: role of MCP-1. Brain Behav Immun (2012) 0.88
Orexin receptor subtype activation and locomotor behaviour in the rat. Acta Physiol (Oxf) (2009) 0.87
Relationship between cancer-related fatigue and physical activity in inpatient cancer rehabilitation. Anticancer Res (2013) 0.86
Functional wiring of hypocretin and LC-NE neurons: implications for arousal. Front Behav Neurosci (2013) 0.85
Ascending caudal medullary catecholamine pathways drive sickness-induced deficits in exploratory behavior: brain substrates for fatigue? Brain Behav Immun (2010) 0.85
Controlled cortical impact traumatic brain injury acutely disrupts wakefulness and extracellular orexin dynamics as determined by intracerebral microdialysis in mice. J Neurotrauma (2012) 0.85
Impact of a home-based walking intervention on outcomes of sleep quality, emotional distress, and fatigue in patients undergoing treatment for solid tumors. Oncologist (2013) 0.84
Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice. Sleep (2013) 0.84
Effects of inflammation produced by chronic lipopolysaccharide administration on the survival of hypocretin neurons and sleep. Brain Res (2004) 0.79
Wake-promoting effects of orexin: Its independent actions against the background of an impaired corticotropine-releasing hormone receptor system. Behav Brain Res (2011) 0.78